Aktis Oncology, Inc. - Common Stock, $0.0001 par value per share (AKTSQ) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2017 to Q2 2025

Type / Class
Equity / Common Stock, $0.0001 par value per share
Symbol
AKTSQ
Shares outstanding
53,311,882
Price per share
$0.01
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Aktis Oncology, Inc. - Common Stock, $0.0001 par value per share (AKTSQ) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
ELI LILLY & Co 12% $63,441 6,344,114 Eli Lilly and Company 12 Jan 2026

Institutional Holders of Aktis Oncology, Inc. - Common Stock, $0.0001 par value per share (AKTSQ) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q2 0 $0 -$186 $0.01 0
2025 Q1 28,756 $186 -$2,201 $0.01 2
2024 Q4 506,064 $2,329 -$1,774,940 $0.00 6
2024 Q3 21,200,599 $1,897,435 -$265,185 $0.09 74
2024 Q2 22,552,604 $2,969,307 -$6,536,132 $0.13 86
2024 Q1 40,766,012 $24,082,620 +$6,776,273 $0.59 114
2023 Q4 28,647,438 $23,897,708 -$3,342,214 $0.83 109
2023 Q3 32,959,953 $24,819,558 -$16,320,918 $0.75 115
2023 Q2 37,359,126 $118,771,428 +$4,954,833 $3.18 129
2023 Q1 35,816,573 $110,320,654 +$32,393,447 $3.08 134
2022 Q4 25,954,942 $73,192,741 -$3,031,899 $2.82 118
2022 Q3 28,084,792 $83,413,629 -$1,955,518 $2.97 116
2022 Q2 28,645,141 $105,984,283 -$2,055,220 $3.70 117
2022 Q1 28,817,875 $187,242,534 +$9,205,739 $6.50 125
2021 Q4 27,471,896 $181,648,914 +$4,764,811 $6.68 144
2021 Q3 26,199,923 $251,078,561 +$15,102,389 $9.70 137
2021 Q2 24,628,830 $262,680,830 +$18,492,366 $10.71 135
2021 Q1 20,871,341 $278,313,970 +$45,493,984 $13.34 140
2020 Q4 17,587,930 $215,095,371 +$34,918,930 $12.23 123
2020 Q3 14,858,398 $121,245,735 -$9,234 $8.16 106
2020 Q2 14,645,331 $121,388,588 +$6,390,914 $8.29 107
2020 Q1 14,541,971 $77,997,627 -$7,393,657 $5.37 92
2019 Q4 14,861,013 $118,892,872 +$41,772,041 $8.00 98
2019 Q3 9,599,971 $74,368,610 -$10,612,495 $7.75 86
2019 Q2 11,160,282 $71,421,311 +$28,509,937 $6.40 74
2019 Q1 6,627,920 $38,504,613 +$3,581,540 $5.81 61
2018 Q4 6,194,754 $30,783,708 +$11,758,455 $4.97 52
2018 Q3 3,358,200 $26,439,108 +$938,131 $7.87 38
2018 Q2 3,246,429 $23,591,651 +$953,511 $7.27 36
2018 Q1 3,172,819 $18,477,690 +$2,383,631 $5.83 41
2017 Q4 2,761,631 $17,215,534 +$2,655,569 $6.23 42
2017 Q3 2,097,337 $13,671,502 +$4,486,379 $6.52 33
2017 Q2 1,389,172 $12,132,953 +$3,180,314 $8.74 28
2017 Q1 742,987 $9,416,000 +$9,416,000 $12.84 13